
## Jake M Pry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/628077/publications.pdf Version: 2024-02-01



INKE M DOV

#	Article	IF	CITATIONS
1	Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clinical Infectious Diseases, 2022, 74, 1382-1389.	5.8	48
2	Severe Acute Respiratory Syndrome Coronavirus 2 and Respiratory Virus Sentinel Surveillance, California, USA, May 10, 2020–June 12, 2021. Emerging Infectious Diseases, 2022, 28, 9-20.	4.3	15
3	Mitigating the effects of COVID-19 on HIV treatment and care in Lusaka, Zambia: a before–after cohort study using mixed effects regression. BMJ Global Health, 2022, 7, e007312.	4.7	8
4	Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021. Morbidity and Mortality Weekly Report, 2022, 71, 212-216.	15.1	116
5	Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure. Clinical Infectious Diseases, 2022, 75, e276-e288.	5.8	21
6	Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia. PLOS Global Public Health, 2022, 2, e0000124.	1.6	1
7	Pilot Implementation of a User-Driven, Web-Based Application Designed to Improve Sexual Health Knowledge and Communication Among Young Zambians: Mixed Methods Study. Journal of Medical Internet Research, 2022, 24, e37600.	4.3	2
8	Profiles of HIV Care Disruptions Among Adult Patients Lost to Follow-up in Zambia: A Latent Class Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 62-72.	2.1	8
9	A pilot case-control study using a one health approach to evaluate behavioral, environmental, and occupational risk factors for chronic kidney disease of unknown etiology in Sri Lanka. One Health Outlook, 2021, 3, 4.	3.4	3
10	Patterns and Predictors of Incident Return to HIV Care Among Traced, Disengaged Patients in Zambia: Analysis of a Prospective Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 313-322.	2.1	16
11	Novel Longitudinal Methods for Assessing Retention in Care: a Synthetic Review. Current HIV/AIDS Reports, 2021, 18, 299-308.	3.1	4
12	Cervical cancer screening outcomes in Zambia, 2010–19: a cohort study. The Lancet Global Health, 2021, 9, e832-e840.	6.3	15
13	Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity. Lancet HIV,the, 2021, 8, e755-e765.	4.7	21
14	The effect of tracer contact on return to care among adult, "lost to followâ€up―patients living with HIV in Zambia: an instrumental variable analysis. Journal of the International AIDS Society, 2021, 24, e25853.	3.0	4
15	Mortality estimates by age and sex among persons living with HIV after ART initiation in Zambia using electronic medical records supplemented with tracing a sample of lost patients: A cohort study. PLoS Medicine, 2020, 17, e1003107.	8.4	12
16	Longitudinal Care Cascade Outcomes Among People Eligible for Antiretroviral Therapy Who Are Newly Linking to Care in Zambia: A Multistate Analysis. Clinical Infectious Diseases, 2020, 71, e561-e570.	5.8	8
17	Participation in adherence clubs and on-time drug pickup among HIV-infected adults in Zambia: A matched-pair cluster randomized trial. PLoS Medicine, 2020, 17, e1003116.	8.4	15
18	Patientâ€reported reasons for declining sameâ€day antiretroviral therapy initiation in routine HIV care settings in Lusaka, Zambia: results from a mixedâ€effects regression analysis. Journal of the International AIDS Society, 2020, 23, e25560.	3.0	11

Jake M Pry

#	Article	IF	CITATIONS
19	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. PLoS ONE, 2020, 15, e0227041.	2.5	15
20	Understanding patient transfers across multiple clinics in Zambia among HIV infected adults. PLoS ONE, 2020, 15, e0241477.	2.5	11
21	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
22	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
23	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
24	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
25	Human-Centered Design Lessons for Implementation Science: Improving the Implementation of a Patient-Centered Care Intervention. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S230-S243.	2.1	55
26	Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti. American Journal of Tropical Medicine and Hygiene, 2019, 100, 392-398.	1.4	5
27	Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a	8.4	20